Loading clinical trials...
Loading clinical trials...
A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Conditions
Interventions
Xanomeline and Trospium Chloride Capsules
Locations
5
United States
Advanced Discovery Research, LLC
Atlanta, Georgia, United States
Seven Counties Services, Inc.
Louisville, Kentucky, United States
Mid Ohio Behavioral Health
Columbus, Ohio, United States
OnSite Clinical Solutions, LLC
Rock Hill, South Carolina, United States
Integrated Clinical Research
St. George, Utah, United States
Start Date
November 8, 2022
Primary Completion Date
March 1, 2023
Completion Date
March 8, 2023
Last Updated
June 12, 2024
NCT06894212
NCT04226898
NCT05240976
NCT07455929
NCT05304767
NCT06745479
Lead Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions